Clinical Glycoproteomics + Artificial Intelligence
Location: United States, California, San Francisco
Total raised: $244.4M
Investors 4
| Date | Name | Website |
| 10.02.2021 | Genoa Vent... | genoavc.co... |
| - | Oriza Vent... | orizaventu... |
| 15.08.2020 | Anzu Partn... | anzupartne... |
| - | Amplify Pa... | amplifypar... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 02.08.2021 | - | $201M | - |
| 16.11.2020 | - | $34M | - |
| 12.12.2018 | - | $9.4M | - |
Mentions in press and media 10
| Date | Title | Description |
| 02.08.2021 | InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development | We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. Cookie settingsACCEPT |
| 03.12.2020 | Slone Partners Places John Leite as Chief Business Officer at InterVenn Biosciences | “John Leite is an experienced and highly accomplished business development and marketing specialist in the biotechnology and diagnostics sectors,” said Slone Partners President Tara Kochis-Stach. SOUTH RIDING, Va. (PRWEB) December 03, 2020 ... |
| 16.11.2020 | Nov 16, 2020 InterVenn Biosciences Raises $34M For Ovarian Cancer, Immuno-oncology Therapies | - |
| 16.11.2020 | InterVenn Biosciences raises $34 million to accelerate cancer test development with AI | InterVenn Biosciences today raised $34 million to further develop its platform for precision medicine. The New York-based startup says the funds will be used to accelerate its go-to-market, expansion, and ongoing product R&D efforts. Ma... |
| 16.11.2020 | InterVenn Biosciences raises $34 million for cancer diagnostics | InterVenn Biosciences, a Redwood City, California-based biotech startup announced today it has raised $34 million in Series B funding to commercialize the diagnostic for ovarian cancer and to also accelerate development efforts for the immu... |
| 16.11.2020 | InterVenn Biosciences Raises $34M to Commercialize Glycoproteomic LDT for Ovarian Cancer and Immuno-oncology | We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. Cookie settingsACCEPT |
| 16.11.2020 | InterVenn Biosciences raises $34 million to accelerate cancer test development with AI | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! InterVenn Biosciences today raised $34 million to... |
| 13.12.2018 | Term Sheet — Thursday, December 13 | THE 2018 STATE OF STARTUPS Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop Here are some of the most interesting takeaways from the report: What is investors’ strongest bias? Founders see... |
| 12.12.2018 | InterVenn BioSciences Raises $9.4M in Funding | InterVenn BioSciences, a Redwood City, Calif.-based life sciences and technology company developing an AI-driven mass spectrometry platform, raised $9.4m in funding. The round was led by biotech investor Genoa Ventures, with participation f... |
| - | Opportunities at the Intersection of Biology, Software, and Automation | Over the past two decades, we’ve seen hundreds of billions of dollars of market capitalization created by new software and infrastructure companies built at the intersection of mobile, data, and cloud computing. Now, we’re in the middle of... |